A clinical trial of proton radiotherapy with local immunotherapy for recurrent cases with hepatocellular carcinoma
Not Applicable
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- JPRN-UMIN000002863
- Lead Sponsor
- Proton Medical Research Center, University of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Initially diagnosed case History of having other malignancies Having autoimmune disorders HIV positive Uncontrollable complications such as infections, heart disorders or psychiatric disorders Administration of anticancer drugs or corticosteroids within 4 months Pregnant Tuberculosis, or hyperreaction in DTH test with the advant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does proton radiotherapy modulate tumor microenvironment to enhance local immunotherapy efficacy in HCC recurrence?
What is the comparative efficacy of proton therapy-immunotherapy combinations versus sorafenib in recurrent hepatocellular carcinoma?
Which biomarkers predict response to proton radiotherapy plus local immunotherapy in JPRN-UMIN000002863 HCC patients?
What are the adverse event profiles and management strategies for proton-immunotherapy synergy in liver cancer?
How does the proton radiotherapy-immunotherapy approach in JPRN-UMIN000002863 compare to PD-1 inhibitors in advanced HCC treatment?